Audentes Therapeutics, Inc.
(NASDAQ : BOLD)

( )
BOLD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.39%295.001.4%$597.51m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
-0.93%67.001.0%$366.36m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%372.162.6%$302.06m
VRTXVertex Pharmaceuticals, Inc.
0.25%220.551.9%$275.13m
CLVSClovis Oncology, Inc.
0.60%13.5114.7%$243.29m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-1.32%67.3211.4%$205.58m
ALXNAlexion Pharmaceuticals, Inc.
2.71%112.472.0%$202.78m
AAgilent Technologies, Inc.
1.73%84.861.6%$165.50m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
SRPTSarepta Therapeutics, Inc.
31.88%132.5014.6%$154.15m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BLUEbluebird bio, Inc.
-3.36%84.0514.2%$136.75m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m

Company Profile

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.